| Title: | Clinical utility of serine proteases in breast cancer |
|---|
| Authors: | ID Čufer, Tanja (Author) |
|---|
| Files: |  PDF - Presentation file, download (108,14 KB)
MD5: 95F416E8073B310397CB6E1BB63831EE
|
|---|
| Language: | English |
|---|
| Typology: | 1.04 - Professional Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | The serine protease uPA and its inhibitor PAI-1 are involved in the degradation of tumor stroma and basement membrane. The independent prognostic value of serine protease urokinase-type plasminogen activator uPA and its inhibitor PAI-1 in breast cancer has been almost uniformly confirmed in numerous individual studies as well as in a meta-analysis, including 18 data sets of more than 8,000 patients. According to these observations, the risk ofrelapse in node negative patients with low levels of uPA and PAI-1 is less then 10%; these patients could be spared from toxic adjuvant systemic therapy.Clinically relevant and even more important is the information that uPA and its inhibitor PAI-1 may also have a predictive value for response to either hormonal or cytotoxic therapy in early breast cancer. According to our data obtained from altogether 460 operable breast cancer patients, uPA and PAI-1 may have a predictive value for the response to hormone therapy, but notto chemotherapy. The high PAI-1 levels were associated with a higher risk of relapse in the patients without adjuvant systemic therapy (HR 2.14; C.I. 95%= 0.48-9.56; p=0.321) and in the patients treated with chemotherapy (RR 2.48; C.1. 95%=1.35-4.57; p=0.003). However, in the patients treated with adjuvant hormone therapy, either alone or in combination with chemotherapy, the prognosric value of uPA and PAI-1 was diminished. Moreover, high levels ofboth uPA and PAI-1 were associated with a lower risk of relapse (HR 0.79; p=0.693 and HR 0.26 p= 0.204, respectively). On the basis of currently available evidence, serine protease uPA and its inhibitor PAI-1 are certainly the markers that improve a proper selection of candidates for adjuvant systemic therapy and may also be the markers that could facilitate treatment decision in each individual patient, which is of utmost importance. |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.06.2004 |
|---|
| Publisher: | Association of Radiology and Oncology |
|---|
| Year of publishing: | 2004 |
|---|
| Number of pages: | str. 85-92 |
|---|
| Numbering: | Letn. 38, št. 2 |
|---|
| Source: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-18147  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 1318-2099 |
|---|
| COBISS.SI-ID: | 18165977 |
|---|
| Copyright: | by Authors |
|---|
| Note: | BSDOCID107826;
|
|---|
| Publication date in DiRROS: | 13.02.2024 |
|---|
| Views: | 545 |
|---|
| Downloads: | 97 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
